8-K - VTAK - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_________________________

FORM 8-K

_________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

December 18, 2023

__________________________

Catheter Precision, Inc.
(Exact name of registrant as specified in its charter)

___________________________

Delaware	001-38677	38-3661826
(State or other jurisdiction<br><br>of incorporation)	(Commission<br><br>File Number)	(IRS Employer<br><br>Identification No.)

1670 Highway 160 West

Suite 205

Fort Mill, SC 29708

(Address of principal executive offices, including zip code)

(973) 691-2000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

_____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	RMED	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On December 18, 2023, Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit	Description
99.1	Press Release Issued on December 18, 2023
104	Cover Page Interactive Data File (formatted as inline XBRL)
2
---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	RA MEDICAL SYSTEMS, INC.
Date: December 18, 2023	By:	/s/ Steven Passey
		Steven Passey
		Chief Financial Officer and Secretary
3
---

rmed_ex991.htm EXHIBIT 99.1

CATHETER PRECISION, INC. Reports Second Quarter Results of Operations

Fort Mill, SC, December 18, 2023 – Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (VTAK: NYSE/American) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the second quarter of 2023.

Highlights of the second quarter include the following:

·	US sales team was assembled, trained, and is creating a pipeline.

| · | Additional US clinical personnel were onboarded and trained. |

| · | Completion of enrollment of 125 patient VIVO patient Registry. Follow-up data is expected to be completed in June 2024. |

| · | Key VIVO accounts continue to be established in both the US and Europe. |

| · | Initiation of first LockeT study, to include 100 patients, to demonstrate time to hemostasis, time to patient ambulation, and time to hospital discharge. This observational study is intended to clinically show a new cost effective alternative to existing closure methods. |

| · | Onboarded a consulting group to bring about international contracts for the distribution of the LockeT closure product. |

| · | Continued pursuit of intellectual property filings for both VIVO and LockeT technologies. |

| · | Total assets at June 30, 2023, were $35.5 million. |

| · | Total cash on hand at June 30, 2023 was $7.4 million. |

| · | Total revenues for the six months ended June 30, 2023 were $181,000. |

| · | Completed the accounting for the merger transaction between Ra Medical Systems and Catheter Precision, including the valuation of the consideration exchanged and the allocation of the purchase price to the different assets and liabilities on the balance sheet, including the various intangible categories. |

David Jenkins, acting CEO, commented: “We are pleased to put the accounting related to the merger behind us, and we now look forward to moving forward as a public company. Our VIVO and LockeT products are now in the introductory stage in the U.S. market, and we are quite satisfied with the initial response. Early commercial feedback has set the stage for greater success over the coming years.”

Mr. Jenkins continued, “We continue to believe that our unique technologies are favorably positioned within the cardiac electrophysiology market. Our VIVO product, an acronym for “View into Ventricular Onset,” is a unique non-invasive mapping system to show early activation in ventricular arrhythmias. We believe that ablation for ventricular arrhythmias has the potential for huge growth, to mirror that of the atrial fibrillation ablation market. VIVO is a tool that, when used in the clinical setting, allows for an accurate visualization and shorter procedure times. LockeT, a suture retention device utilized after percutaneous venous access, is easy to use and comfortable for the patient. Early clinical use has demonstrated short times to achieve hemostasis and to ambulation at a lower cost to the hospital than other closure devices. The first study, to include 125 patients, is expected to be available soon.”

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Reincorporated as Ra Medical Systems, Inc. in Delaware in 2018, the Company changed its name to Catheter Precision, Inc. on August 17, 2023.

1

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, our expectations regarding the potential for the growth of ablation for ventricular arrhythmias, and the Company’s potential for future success. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2022 and Forms 10-Q for the quarters ended March 31, 2023 and June 30, 2023, filed with the U.S. Securities and Exchange Commission and available at www.sec.gov. These risks and uncertainties include, but aren’t limited to, that we will not be able to reach profitability unless we are able to achieve our product expansion and growth goals, our research and development and commercialization efforts may depend on entering into agreements with corporate collaborators, we have entered into joint marketing agreements with respect to our products, and may enter into additional join marketing agreements, that will reduce our revenues from product sales, royalty agreements with respect to our LockeT device will reduce any future profits from this product, if we experience significant disruptions in our information technology systems, our business may be adversely affected, litigation and other legal proceedings may adversely affect our business, if we make acquisitions or divestitures, we could encounter difficulties that harm our business, failure to attract and retain sufficient qualified personnel could also impede our growth, failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock, if our internal controls are not effective, we may not be able to accurately report our financial results or prevent fraud, our revenues may depend on our customers’ receipt of adequate reimbursement from private insurers and government sponsored healthcare programs, we may be unable to compete successfully with companies in our highly competitive industry, many of whom have substantially greater resources than we do, our future operating results depend upon our ability to obtain components in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality and volumes that are acceptable to us, and suppliers may fail to deliver components, or we may be unable to manage these components effectively or obtain these components on such terms, if hospitals, physicians and patients do not accept our current and future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any, our medical device operations are subject to pervasive and continuing FDA regulatory requirements, our products may be subject to additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, changes in trade policies among the U.S. and other countries, in particular the imposition of new or higher tariffs, could place pressure on our average selling prices as our customers seek to offset the impact of increased tariffs on their own products, increased tariffs or the imposition of other barriers to international trade could have a material adverse effect on our revenues and operating results.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

CONTACTS:

At the Company

David Jenkins

973-691-2000

mhuck@catheterprecision.com

# # #

2

CATHETER PRECISION, INC. (formerly known as RA MEDICAL SYSTEMS, INC.)

Condensed Consolidated Statements of Operations

(in thousands, except share and par value data)

(Unaudited)

	For the Three Months Ended<br> <br>June 30,						For the Six Months Ended<br> <br>June 30,

| | 2023 | | | 2022 | | | 2023 | | | 2022 | | | | Revenues | | | | | | | | | | | | |

| Product sales | $ | 96 | | $ | 5 | | $ | 181 | | $ | 14 | |

| Product sales | | 7 | | | 11 | | | 17 | | | 42 | |

| Service and other | | - | | | 55 | | | - | | | 119 | |

| Total cost of revenues | | 7 | | | 66 | | | 17 | | | 161 | |

| Gross profit (loss) | | 89 | | | (61 | ) | | 164 | | | (147 | ) |

| Selling, general and administrative | | 1,415 | | | 2,476 | | | 11,648 | | | 4,778 | |

| Research and development | | 134 | | | 2,396 | | | 374 | | | 5,511 | |

| Restructuring and impairment | | - | | | 3,527 | | | - | | | 3,527 | |

| Loss on impairment of goodwill | | 4,848 | | | - | | | 60,934 | | | - | |

| Total operating expenses | | 6,397 | | | 8,399 | | | 72,956 | | | 13,816 | |

| Operating loss | | (6,308 | ) | | (8,460 | ) | | (72,792 | ) | | (13,963 | ) |

| Change in fair value of royalty payable | | 4,617 | | | - | | | 4,617 | | | - | |

| Interest income | | 119 | | | - | | | 188 | | | - | |

| Other (expense) income, net | | (4 | ) | | 12 | | | 11 | | | 20 | |

| Total other income, net | | 4,732 | | | 12 | | | 4,816 | | | 20 | |

| Loss from operations before income taxes | | (1,576 | ) | | (8,448 | ) | | (67,976 | ) | | (13,943 | ) |

| Income taxes | | - | | | - | | | - | | | - | |

| Net loss | $ | (1,576 | ) | $ | (8,448 | ) | $ | (67,976 | ) | $ | (13,943 | ) |

| Deemed dividends from the warrant inducement offer | | - | | | - | | | (800 | ) | | - | |

| Net loss attributable to common stockholders | $ | (1,576 | ) | $ | (8,448 | ) | $ | (68,776 | ) | $ | (13,943 | ) |

| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.29 | ) | $ | (13.07 | ) | $ | (16.97 | ) | $ | (0.03 | ) |

| Weighted average common shares used in computing net loss per share, basic and diluted | | 5,364,383 | | | 646,361 | | | 4,052,700 | | | 525,924 | |

3

CATHETER PRECISION, INC. (formerly known as RA MEDICAL SYSTEMS, INC.)

Condensed Consolidated Balance Sheets

(in thousands, except share and par value data)

			December 31,<br> <br>2022

| Cash and cash equivalents | 7,410 | | $ | 15,859 | |

| Accounts receivable, net | 119 | | | - | |

| Inventories | 59 | | | - | |

| Prepaid expenses and other current assets | 320 | | | 977 | |

| Total current assets | 7,908 | | | 16,836 | |

| Property and equipment, net | 67 | | | - | |

| Operating lease right-of-use assets | 220 | | | - | |

| Intangible assets, net | 27,339 | | | - | |

| Other non-current assets | 8 | | | - | |

| TOTAL ASSETS | 35,542 | | $ | 16,836 | | | LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | |

| Accounts payable | 93 | | $ | 92 | |

| Accrued expenses | 1,863 | | | 7,484 | |

| Current portion of operating lease liabilities | 86 | | | - | |

| Total current liabilities | 2,042 | | | 7,576 | |

| Royalties payable | 9,565 | | | - | |

| Operating lease liabilities | 144 | | | - | |

| Total liabilities | 11,751 | | | 7,576 | |

| Commitments and contingencies (see Note 16) | | | | | |

| Series A Convertible Preferred Stock, 0.0001 par value, 10,000,000 shares authorized; 7,203 and 0 shares issued and outstanding as June 30, 2023 and December 31, 2022, respectively | - | | | - | |

| Series X Convertible Preferred Stock, 0.0001 par value, 15,404 shares authorized; 12,675 and 0 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | - | | | - | |

| Common stock, 0.0001 par value, 300,000,000 shares authorized; 5,367,674 and 2,161,950 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | - | | | - | |

| Additional paid-in capital | 296,904 | | | 214,397 | |

| Accumulated deficit | (273,113 | ) | | (205,137 | ) |

| Total stockholders' equity | 23,791 | | | 9,260 | |

| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 35,542 | | $ | 16,836 | |

All values are in US Dollars.

4